Background

Amanda is an infectious diseases physician who completed advanced training at The Alfred and Geelong Hospitals.

Since obtaining her fellowship, she has worked at Barwon Health and taught at Deakin University.

Amanda has an interest in blood-borne viruses and sexually transmitted infections, and has been working in the sexual health and liver clinics at Barwon Health for some years.

Recently she started managing the liver clinic, which provides viral hepatitis services to the area.

She was awarded her PhD in 2018 after investigating models of care for hepatitis C in the era of directly-acting antivirals. Professor Margaret Hellard AM was her primary supervisor.

Amanda’s goal is to increase hepatitis C service provision for those in regional and rural areas.

Positions

• Director, Liver clinic, Barwon Health
• Infectious diseases physician, Barwon Health

Qualifications

• 2018: PhD
• 2008: FRACP (Infectious Diseases)
• 1999: MBBS (Hons), Monash

Projects (4)

Current (3)

• 

  Hepatitis C brief reports

• 

  The elimination of hepatitis C as a global public health threat

• 

  The QuickStart Study

Publications (20)

2021 (2)

• Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for HCV NS5A-inhibitor experienced patients with difficult to cure characteristics.
  Papaluca T, Roberts SK, Strasser SI, Stuart KA, Farrell G, MacQuillan G, Dore GJ, Wade AJ, George J, Hazeldine S, O'Beirne J, Wigg A, Fisher L, McGarity B, Sawhney R, Sinclair M, Thomas J, Valiozis I, Weltman M, Wilson M, Woodward A, Ahlenstiel G, Haque M, Levy M, Prewett E, Sievert W, Sood S, Tse E, Valaydon Z, Bowden S, Douglas M, New K, O'Keefe J, Hellard M, Doyle J, Stoové M, Thompson AJ
  Clin Infect Dis. 2021 Jan; Epub ahead of print
• In support of community-based hepatitis C treatment with triage of people at risk of cirrhosis to specialist care.
  Wade AJ, Doyle JS, Draper B, Howell J, Iser D, Roberts SK, Kemp W, Thompson AJ, Hellard ME
  J Viral Hepat. 2021 Jan; 28(1):217-218

2020 (5)

• A survey of Australian general practitioners' hepatitis C knowledge and management 2 years after subsidised direct-acting antiviral therapy became available.
  Gooey M, Wong E, Pedrana A, Allard N, Doyle J, Hellard M, Wade A
  Sex Health. 2020 Aug; 17(4):387-389
• Can community pharmacists treat hepatitis C virus?
  Wade AJ
  Lancet Gastroenterol Hepatol. 2020 Jun; 5(9):790-791
• Australia needs to increase testing to achieve hepatitis C elimination.
  Scott N, Sacks-Davis R, Wade AJ, Stoové M, Pedrana A, Doyle JS, Thompson AJ, Wilson DP, Hellard ME
  Med J Aust. 2020 Mar; 212(8):365-370
• A cost-effectiveness analysis of primary versus hospital-based specialist care for direct acting antiviral hepatitis C treatment.
  Palmer AY, Wade AJ, Draper B, Howell J, Doyle JS, Petrie D, Thompson AJ, Wilson DP, Hellard ME, Scott N
  Int J Drug Policy. 2020 Feb; 76:102633
• Outcomes of treatment for hepatitis C in primary care compared to hospital-based care: a randomised controlled trial in people who inject drugs.
  Wade AJ, Doyle JS, Gane E, Stedman C, Draper B, Iser D, Roberts SK, Kemp W, Petrie D, Scott N, Higgs P, Agius PA, Roney J, Stothers L, Thompson AJ, Hellard ME
  Clin Infect Dis. 2020 Jan; 70(9):1900-1906

2018 (4)

• Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trial.
  Wade AJ, Doyle JS, Gane E, Stedman C, Draper B, Iser D, Roberts SK, Kemp W, Petrie D, Scott N, Higgs P, Agius PA, Roney J, Stothers L, Thompson AJ, Hellard ME
  Trials. 2018 Jul; 19(1):383
• Health issues of refugees attending an infectious disease refugee health clinic in a regional Australian hospital
  Masters PJ, Lanfranco PJ, Sneath E, Wade AJ, Huffam S, Pollard J, Standish J, McCloskey K, Athan E, O'Brien DP, Friedman ND
  Aust J Gen Pract. 2018 May; 47(5):305-310
• Aiming for elimination: outcomes of a consultation pathway supporting regional general practitioners to prescribe direct acting antiviral therapy for hepatitis C.
  Wade AJ, McCormack A, Roder C, McDonald K, Davies M, Scott N, Wardrop M, Athan E, Hellard ME
  J Viral Hepat. 2018 Apr; 25(9):1089-1098
• Heterogeneity in hepatitis C treatment prescribing and uptake in Australia: a geospatial analysis of a year of unrestricted treatment access.
  Scott N, Hainsworth SW, Sacks-Davis R, Pedrana A, Doyle J, Wade A, Hellard M
  J Virus Erad. 2018 Apr; 4(2):108-114

2017 (1)

• A survey of hepatitis C management by Victorian GPs after PBS-listing of direct-acting antiviral therapy.
  Wade A, Draper B, Doyle J, Allard N, Grinzi P, Thompson A, Hellard M
  Aust Fam Physician. 2017 Apr; 46(4):235-240

2016 (1)

• A systematic review of community based hepatitis C treatment.
  Wade AJ, Veronese V, Hellard ME, Doyle JS.
  BMC Infect Dis. 2016 May; 16(1):202

2015 (1)

• The Cascade of Care for an Australian Community-Based Hepatitis C Treatment Service.
  Wade AJ, Macdonald DM, Doyle JS, Gordon A, Roberts SK, Thompson AJ, Hellard ME
  PLoS One. 2015 Nov; 10(11):e0142770

2010 (1)

• Ribavirin and Viramidine (Book Chapter)
  Wade AJ, Sasadeausz J
  in Kucers’ The Use of Antibiotics, 6th Edition, Hodder-Arnold. 2010 Jul

2007 (2)

• Chlamydia trachomatis prevalence in heterosexual men in Melbourne: a community-based study.
  Wade AJ, Hocking LS, Hellard ME
  Sex Health. 2007 Jun; 4(2):137-138
• Leptospirosis: an unusual presentation.
  Amanda J Wade, David V Tuxen, Steven L Wesselingh
  Crit Care Resusc. 2007 Mar; 9(1):108

2006 (3)

• Postoperative enteritis due to methicillin-resistant Staphylococcus aureus.
  Allenc Cheng, Amanda Wade, Owenc Harris, Conrad Brandt, Eugene Athan
  ANZ J Surg. 2006 Aug; 76(8):763
• Spontaneous splenic rupture: a rare complication of Q fever in Australia.
  Amanda J Wade, Tim Walker, Eugene Athan, Andrew J Hughes
  Med J Aust. 2006 Apr; 184(7):364
• Q fever outbreak at a cosmetics supply factory.
  Amanda J Wade, Allen C Cheng, Eugene Athan, Jo L Molloy, Owen C Harris, John Stenos, Andrew J Hughes
  Clin Infect Dis. 2006 Apr; 42(7):e50-e52

News Articles (2)

2020 (1)

• Testing rate fall leaves thousands of Australians at risk of hepatitis C

2019 (1)

• Hepatitis C treatment in primary care crucial to elimination